Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acceleron Pharma (XLRN)

Acceleron Pharma (XLRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,931,634
  • Shares Outstanding, K 61,156
  • Annual Sales, $ 92,520 K
  • Annual Income, $ -166,030 K
  • 60-Month Beta 0.13
  • Price/Sales 118.77
  • Price/Cash Flow N/A
  • Price/Book 15.16
Trade XLRN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.17
  • Most Recent Earnings -1.16 on 11/04/21
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00%
  • Historical Volatility 12.11%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.85
  • Number of Estimates 7
  • High Estimate -0.50
  • Low Estimate -1.16
  • Prior Year -0.95
  • Growth Rate Est. (year over year) +10.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
172.25 +3.77%
on 10/20/21
179.94 -0.66%
on 11/17/21
+5.01 (+2.88%)
since 10/19/21
3-Month
120.20 +48.71%
on 08/20/21
189.99 -5.92%
on 09/29/21
+58.76 (+48.97%)
since 08/19/21
52-Week
108.82 +64.26%
on 11/20/20
189.99 -5.92%
on 09/29/21
+67.83 (+61.15%)
since 11/19/20

Most Recent Stories

More News
Merck Completes Acquisition of Acceleron Pharma Inc.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN).

MRK : 73.21 (+1.29%)
XLRN : 178.75 (-0.52%)
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding...

MRK : 73.21 (+1.29%)
XLRN : 178.75 (-0.52%)
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we”...

XLRN : 178.75 (-0.52%)
MRK : 73.21 (+1.29%)
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in...

MRK : 73.21 (+1.29%)
XLRN : 178.75 (-0.52%)
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we”...

XLRN : 178.75 (-0.52%)
MRK : 73.21 (+1.29%)
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its pending acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN) has been cleared by the competition authorities...

MRK : 73.21 (+1.29%)
XLRN : 178.75 (-0.52%)
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

XLRN : 178.75 (-0.52%)
Acceleron: Q3 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Thursday reported a loss of $70.5 million in its third quarter.

XLRN : 178.75 (-0.52%)
Acceleron Reports Third Quarter 2021 Financial Results

Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases,...

XLRN : 178.75 (-0.52%)
MRK : 73.21 (+1.29%)
Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)

Acceleron Pharma (XLRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

XLRN : 178.75 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 182.84
2nd Resistance Point 181.34
1st Resistance Point 180.05
Last Price 178.75
1st Support Level 177.26
2nd Support Level 175.76
3rd Support Level 174.47

See More

52-Week High 189.99
Last Price 178.75
Fibonacci 61.8% 158.98
Fibonacci 50% 149.40
Fibonacci 38.2% 139.83
52-Week Low 108.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar